News
SRPT
17.24
-3.25%
-0.58
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN), Shattuck Labs (STTK) and Sarepta Therapeutics (SRPT)
TipRanks · 15h ago
Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (OtherSEMHF), Sarepta Therapeutics (SRPT) and Nkarta (NKTX)
TipRanks · 15h ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Zimmer Biomet Holdings (ZBH), Brookdale Senior Living (BKD) and Sarepta Therapeutics (SRPT)
TipRanks · 16h ago
Weekly Report: what happened at SRPT last week (1102-1106)?
Weekly Report · 17h ago
Is Sarepta Therapeutics (SRPT) Undervalued Following Raised 2026 Guidance And Mixed Quarterly Results?
Simply Wall St · 2d ago
Analysts Conflicted on These Healthcare Names: Elicio Therapeutics (ELTX), Amphastar Pharmaceuticals (AMPH) and Sarepta Therapeutics (SRPT)
TipRanks · 2d ago
Will Narrower Losses Change Sarepta Therapeutics Stock Narrative
Simply Wall St · 3d ago
Sarepta Therapeutics Is Maintained at Sector Perform by RBC Capital
Dow Jones · 3d ago
Sarepta Therapeutics Price Target Raised to $18.00/Share From $17.00 by RBC Capital
Dow Jones · 3d ago
RBC Capital Maintains Sector Perform on Sarepta Therapeutics, Raises Price Target to $18
Benzinga · 3d ago
Sarepta-Hansa Gene Therapy Study Ends, Raising Questions for Investors
TipRanks · 3d ago
Sarepta (SRPT) Q3 2026 Earnings Call Transcript
The Motley Fool · 3d ago
Morgan Stanley Gives a Hold Rating to Sarepta Therapeutics (SRPT)
TipRanks · 3d ago
Oppenheimer Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)
TipRanks · 3d ago
Dyne Therapeutics: Buy Rating Reaffirmed on Clinical Catalysts and Strong Commercial Momentum; $35 Price Target Unchanged
TipRanks · 3d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Tandem Diabetes Care (TNDM), Sarepta Therapeutics (SRPT) and Krystal Biotech (KRYS)
TipRanks · 3d ago
Piper Sandler Sticks to Its Hold Rating for Sarepta Therapeutics (SRPT)
TipRanks · 3d ago
Sarepta: Sell Reiterated as ELEVIDYS Erosion Weighs on Outlook; $5 Price Target Unchanged
TipRanks · 3d ago
Sarepta price target lowered to $18 from $20 at Baird
TipRanks · 3d ago
Sarepta Therapeutics (SRPT) Q3 Earnings Lag Estimates
NASDAQ · 4d ago
More
Webull provides a variety of real-time SRPT stock news. You can receive the latest news about Sarepta Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS.